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Schwannomas, meningiomas and ependymomas are tumours of the nervous system which 
occur sporadically or as part of the hereditary disease Neurofibromatosis type 2.  Mutations 
in Neurofibromin 2/NF2 gene cause all NF2-related schwannomas, meningiomas and 
ependymomas, 77% sporadic schwannomas, 60% sporadic meningiomas and 30% sporadic 
ependymomas1 . Schwannomas are the hallmark of NF2 and develop in all NF2 patients. 
Current treatments for NF2-related tumours are surgery or radiosurgery. Radiation may 
induce additional mutations and formation of secondary tumours in NF2 whereas surgery has 
limited use in patients with high tumour load or tumours located at the sites where resection 
would cause neurological complications1. Avastin is effective but only in a fraction of 
patients1. Published consensus recommendations suggest that the development of effective 
therapies for NF2 is urgent, with great potential for clinical progress1. 
Platelet-derived growth factor receptor β (PDGFRβ) is overexpressed and activated in human 
primary schwannoma cells leading to to increased proliferation2. Using orally available, FDA 
approved cRAF/ VEGFR-2/PDGFR-β inhibitor, Sorafenib this was successfully inhibited in 
vitro 2. 
This was an open label, phase 0, single agent trial (EudraCT: 2011-001789-16, REC: 
11/LO/0771) testing Sorafenib in NF2 patients with the aim to determine whether molecular 
target inhibition occurs with oral sorafenib in NF2 patients and  whether target inhibition in 






Per protocol minimal recruitment target depending on the PD response rate was 3 patients (2 out of 3 
or 3 out of 5 with 60% PD response4). Here five adult NF2 patients with peripheral 
schwannomas (PS), diagnosed according to NIH Diagnostic Criteria for Neurofibromatosis, 
were treated with Sorafenib administered orally at maximum tolerated dose (MTD) of 
400mg, twice daily, for 10 days, and with a single 400mg dose on day 11 and two different 
(except 1 patient) peripheral schwannomas biopsied at day 0 and 11 as part of the trial 
protocol. The steady-state plasma concentrations and intra-tumoural concentrations of 
Sorafenib (primary outcome) in PS were measured after the treatment (North East 
Bioanalytical Laboratories, Hamden, CT, USA). The co-primary outcome was efficacy of 
Sorafenib on target inhibition. This was assessed by determining the levels of 
active/phosphorylated PDGFRβ, ERK1/2, AKT and S6 Ribosomal Protein (ps6), expression 
of proliferation marker cyclin D1, apoptosis marker cleaved caspase-3 in PS and the levels of 
active/phosphorylated PDGFRβ, ERK1/2, AKT in peripheral blood mononuclear cells 
(PBMCs) before and after treatment in each patient. Methods used were western blotting and 
immunohistochemistry (IHC)3.  Evidence for a reduction in each molecular target of 
Sorafenib was sought from one-sided t-tests performed, using R version 3.3.3, on the log-
transformed ratios of the before-and-after measurements, which assumed a common variance 
for each marker pooled from across the patients. According to the phase 0 design of Murgo et 
al.4 the mean logged ratios of at least three out of five patients had to be less than zero to 





Most patients experienced mild-moderate adverse events using CTCAE, (Supplementary 
table 1). Sorafenib was detected at 3316.9 -20792.2 ng/ml in plasma and 1425.9 -6242.1 ng/g 
in PS samples from all NF2 patients similar to other trials (Supplementary table 2).  
Western blot analysis of PS samples from five patients demonstrated non-significant changes 
of pPDGFRβY857 in all patients (Figure 1A);  non-significant changes of pERK1/2 (Figure 
1B) in four patients and significant reduction in one patient; non-significant changes of 
pAKTS473 in all five patients (Figure 1C); non-significant changes of ps6 in  three patients  
and significant reduction in two (Figure 1D); non-significant changes of cyclin D1 (Figure 
1E), cleaved caspase-3 (Figure 1F) and total ERK1/2 and AKT (Supplementary figure 1A 
and C ) in all five patients. Results from PBMC: pPDGFRβY857 (Figure 1G), pERK1/2 
(Figure 1H), pAKTS473 (Figure 1I), total ERK1/2 and total AKT (Supplementary figure 1B 
and D) showed no significant changes.  
Additional semi-quantitative immunohistochemistry demonstrated decreased pPDGFRβY857 
staining in PS samples from two patients, pERK1/2 in four and cleaved caspase-3 in one 
(Figure 1J). No changes in pAKT S473 (Figure 1J) were observed.  Sorafenib increased 
number of proliferating cells (MIB1) in PS tissues from three patients and had no effect in 
two (Supplementary figure 1E). It also increased number of intratumoural macrophages 
(CD68) in PS tissue from one patient and decreased in PS tissues from two patients 
(Supplementary figure 1E). The number of or tumour-infiltrating CD3+T-cells increased in 
tissue samples from four patients (Supplementary figure 1E). Double staining for MIB1 and 
macrophage marker CD63, and MIB1 and T-cell marker CD3 revealed that the majority of 
proliferating cells were tumour cells although, in two cases, up to 24% were macrophages. 
No proliferating lymphocytes were observed (Supplementary figure 1E). 
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No correlation between target inhibition and drug concentrations in PS and in plasma were 
observed. 
Discussion  
To select the right drug to take forward into larger clinical trials in NF2 patients we report the 
first phase 0 clinical trial4 allowing rapid assessment of the usefulness of Sorafenib. Our 
within-patient measurements allowed a direct estimate of patient-specific variability.  
We show that at standard MTD (400mg, twice daily), Sorafenib was detected in plasma 
(3316.9-20792.2 ng/ml) and in tumour tissue (1425.9 -6242.1ng/g) in all patients. At MTD 
Sorafenib caused adverse events in all patients including fatigue, diarrhoea/constipation and 
rash which were mostly mild to moderate but in one patient rash was severe. 
Pharmacodynamics (PD) effects, even at MTD with reasonable bioavailability, were lower 
than expected from our preclinical in vitro studies in human primary schwannoma cells 
where Sorafenib was highly effective2. The primary PD endpoint was negative since samples 
from only two out of five patients displayed significant results. Immunohistochemistry 
staining for MIB1/Ki67 revealed no changes in proliferation upon Sorafenib treatment in two 
patients and a slight increase in three patients. This increase is potentially due to 
accumulation of MIB1/Ki67-positive macrophages and active tumour-infiltrating CD8+T 
cells5. Post-treatment PS samples demonstrated increased macrophages and T cells which 
agrees with previous studies5. Double staining for MIB1/Ki67, macrophage marker CD63 
and, MIB1/Ki67 and T-cell marker CD3 revealed that most of proliferating cells were tumour 
cells. However, a percentage of CD63 positive macrophages double stained with MIB1. No 
CD3 positive cells co-stained with MIB1. Thus, lack of reduction or slightly increased 




This study demonstrates that Sorafenib, can be detected in plasma and in PS and its effect on 
target inhibition can be successfully determined confirming the usefulness of Phase 0 trials in 
NF2 patients. However, despite some PD effects the trial was negative for the primary 
outcome and patients experienced relevant side effects.  
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Analysis of the efficacy of Sorafenib in target inhibition in peripheral schwannoma samples 
(PS; western blotting and immunohistochemistry) and peripheral blood mononuclear cells 
(PBMCs; western blotting) from Neurofibromatosis type 2 (NF2) patients. (A) Sorafenib had 
no significant effect on pPDGFRβ in PS samples of any patients (5/5). (B) No significant 
changes of pERK1/2 were observed in PS samples from four patients (4/5) and significant 
reduction of pERK1/2 was detected in PS sample from one patient (1/5). (C) pAKT S473 did 
not significantly change in PS samples from any patients (5/5). (D) No significant changes of 
ps6 were observed in PS samples from three patients (3/5) and significant reduction was 
detected in PS samples from two patients (2/5). (E and F) Cyclin D1 and cleaved caspase-3 
were not significantly changed in PS samples from any of patients (5/5). (G-I) All results 
from PBMC: pPDGFRβ (G), pERK1/2 (H) and pAKT S473 (I) showed no significant change 
in any of patients. (J) Immunohistochemistry demonstrated decreased pPDGFRβ staining in 
PS samples from two patients (2/5), pERK1/2 in four (4/5) and Cleaved caspase 3 in one 
(1/5). No significant changes in pAKT S473 were observed in any of patients.  Technical 
repeats:  Patient1, n=5 (A), n=5 (B), n=3 (C), n=4 (D), n=1 (E), n=3 (F), n=5 (G), n=5 (H), 
n=5 (J); Patients 2, n=5 (A), n=6 (B), n= 7 (C), n=3 (D), n=3 (E), n=3 (F), n=3 (G), n=4 (I);  
Patient 3, n=4 (A), n=6 (B), n=6 (C), n=3 (D), n=5 (E), n=4 (F), n=3 (G), n=5 (H), n=5 (I); 
Patient 4, n=4 (A), n= 3 (B), n=4 (C), n=8 (D), n=6 (E), n=5 (F), n=3 (G), n=1 (H), n=4 (I); 
Patient 5, n=6 (A), n=3 (B), n=4 (C), n=5 (D), n=7 (E), n=5 (F). 
Supplementary figure 1 
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Expression of AKT S473 and ERK1/2 in PS tissues and PBMC samples, and the number of 
MIB positive cells in PS tissues from NF2 patients before (Day 0) and after (Day 11) 
treatment with Sorafenib. (A and C) Western blot on fresh biopsy samples demonstrates non- 
significant changes in ERK1/2 and AKT expression after the treatment in all patients (5/5). 
(B and D) Western blot on fresh PBMC samples demonstrates non-significant changes of 
ERK1/2 and non-significant changes of AKT in four out of four patients after the treatment. 
(E) MIB1 staining increases in three patients (3/5) when estimated in average proliferating 
area. The number of CD63 and MIB1 positive cells increases in all the patients (5/5) and no 
CD3 cells are MIB1 positive. (A-D) Technical repeats: Patient 1, n=5 (A), n=3 (B), n=3 (C) 
and n=4 (D); Patient 2, n=5 (A), n=1 (B), n=4 (C) and n=1 (D); Patient 3, n=5 (A), n=4 (C); 
n=1 (D). Patient 4, n=5 (A), n=4 (B), n=5 (C), n=5 (D). Patients 5, n=6 (A), n=5 (C). 
